Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis

被引:20
作者
Matute-Blanch, Clara [1 ]
Rio, Jordi [1 ]
Villar, Luisa M. [2 ]
Midaglia, Luciana [1 ]
Malhotra, Sunny [1 ]
Alvarez-Cermeno, Jose C. [2 ]
Vidal-Jordana, Angela [1 ]
Montalban, Xavier [1 ]
Comabella, Manuel [1 ]
机构
[1] Univ Autonoma Barcelona, Hosp Univ Vall Hebron, Ctr Esclerosi Multiple Catalunya Cemcat, Inst Recerca Vall Hebron VHIR,Servei Neurol Neuro, Barcelona, Spain
[2] Hosp Univ Ramon & Cajal, Inst Ramon & Cajal Invest Sanitaria, Dept Neurol & Immunol, Madrid, Spain
关键词
Chitinase; 3-like; 1; Interferon-beta; Glatiramer acetate; Biomarkers; Multiple sclerosis; BIOMARKER; PREDICT; FAMILY;
D O I
10.1016/j.jneuroim.2016.12.006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Chitinase 3-like 1 (CHI3L1) plays a prognostic role in patients with multiple sclerosis (MS). Here, we investigated a potential association between CHI3L1 and the response to interferon-beta (IFN beta) and glatiramer acetate (GA). Serum CHI3L1 levels were measured by ELISA in 117 relapsing-remitting MS (RRMS) patients, 76 IFN beta-treated and 41 GA-treated patients. CHI3L1 levels were increased by GA (p = 0.014) but unchanged by IFN beta (p =0.830). CHI3L1 was associated with IFN beta, response and levels were higher in non-responder group (p 0.020), while GA showed no responder effect (p = 0.943). These results suggest a role for CHI3L1 as response biomarker to IFN beta in RRMS patients. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:62 / 65
页数:4
相关论文
共 11 条
[1]   Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis [J].
Canto, E. ;
Reverter, F. ;
Morcillo-Suarez, C. ;
Matesanz, F. ;
Fernandez, O. ;
Izquierdo, G. ;
Vandenbroeck, K. ;
Rodriguez-Antigueedad, A. ;
Urcelay, E. ;
Arroyo, R. ;
Otaegui, D. ;
Olascoaga, J. ;
Saiz, A. ;
Navarro, A. ;
Sanchez, A. ;
Dominguez, C. ;
Caminero, A. ;
Horga, A. ;
Tintore, M. ;
Montalban, X. ;
Comabella, M. .
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (07) :983-990
[2]   Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes [J].
Canto, Ester ;
Tintore, Mar ;
Villar, Luisa M. ;
Costa, Carme ;
Nurtdinov, Ramil ;
Alvarez-Cermeno, Jose C. ;
Arrambide, Georgina ;
Reverter, Ferran ;
Deisenhammer, Florian ;
Hegen, Harald ;
Khademi, Mohsen ;
Olsson, Tomas ;
Tumani, Hayrettin ;
Rodriguez-Martin, Eulalia ;
Piehl, Fredrik ;
Bartos, Ales ;
Zimova, Denisa ;
Kotoucova, Jolana ;
Kuhle, Jens ;
Kappos, Ludwig ;
Antonio Garcia-Merino, Juan ;
Jos Sanchez, Antonio ;
Saiz, Albert ;
Blanco, Yolanda ;
Hintzen, Rogier ;
Jafari, Naghmeh ;
Brassat, David ;
Lauda, Florian ;
Roesler, Romy ;
Rejdak, Konrad ;
Papuc, Ewa ;
de Andres, Clara ;
Rauch, Stefan ;
Khalil, Michael ;
Enzinger, Christian ;
Galimberti, Daniela ;
Scarpini, Elio ;
Teunissen, Charlotte ;
Sanchez, Alex ;
Rovira, Alex ;
Montalban, Xavier ;
Comabella, Manuel .
BRAIN, 2015, 138 :918-931
[3]  
HAKALA BE, 1993, J BIOL CHEM, V268, P25803
[4]   Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis [J].
Hinsinger, G. ;
Galeotti, N. ;
Nabholz, N. ;
Urbach, S. ;
Rigau, V. ;
Demattei, C. ;
Lehmann, S. ;
Camu, W. ;
Labauge, P. ;
Castelnovo, G. ;
Brassat, D. ;
Loussouarn, D. ;
Salou, M. ;
Laplaud, D. ;
Casez, O. ;
Bockaert, J. ;
Marin, P. ;
Thouvenot, E. .
MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (10) :1251-1261
[5]  
Johansen JS, 2006, DAN MED BULL, V53, P172
[6]  
Kawada Mayumi, 2007, Keio Journal of Medicine, V56, P21, DOI 10.2302/kjm.56.21
[7]   Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis [J].
Modvig, S. ;
Degn, M. ;
Roed, H. ;
Sorensen, T. L. ;
Larsson, H. B. W. ;
Langkilde, A. R. ;
Frederiksen, J. L. ;
Sellebjerg, F. .
MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (14) :1761-1770
[8]   Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages [J].
Renkema, GH ;
Boot, RG ;
Au, FL ;
Donker-Koopman, WE ;
Strijland, A ;
Muijsers, AO ;
Hrebicek, M ;
Aerts, JMFG .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1998, 251 (1-2) :504-509
[9]   Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon β:: Implications for clinical trials [J].
Río, J ;
Nos, C ;
Tintoré, M ;
Borrás, C ;
Galán, I ;
Combella, M ;
Montalban, X .
ANNALS OF NEUROLOGY, 2002, 52 (04) :400-406
[10]   Measures in the first year of therapy predict the response to interferon β in MS [J].
Rio, J. ;
Castillo, J. ;
Rovira, A. ;
Tintore, M. ;
Sastre-Garriga, J. ;
Horga, A. ;
Nos, C. ;
Comabella, M. ;
Aymerich, X. ;
Montalban, X. .
MULTIPLE SCLEROSIS, 2009, 15 (07) :848-853